论文信息 - Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC). - 字舞流文

Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).

T. Choueiri | G. Sonpavde | P. Ravi | R. Jain | J. Merchan | W. Tan | W. P. Skelton | C. Curran | C. Mantia | A. Nassar | E. Akl | Trisha M. Plastini | D. Freeman | E. Adib